BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer

Bibliography

• Carmeliet P, Jain R. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57
   PubMed Web of Science ®Google Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82(1):4-6
   PubMed Web of Science ®Google Scholar
• Hicklin D, Ellis L. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23(5):1011-27
   PubMed Web of Science ®Google Scholar
• Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol 1998;184:119-22
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611
   PubMed Web of Science ®Google Scholar
• Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69(Suppl 3):4-10
   PubMed Web of Science ®Google Scholar
• Bremnes R, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51(2):143-58
   PubMed Web of Science ®Google Scholar
• Jain R. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9
   PubMed Web of Science ®Google Scholar
• Giaccone G. The potential of antiangiogenic therapy in non-small cell lung cancer. Clin Cancer Res 2007;13:1961-70
   PubMed Web of Science ®Google Scholar
• Clement-Duchene C, Wakelee H. Antiangiogenic agents and vascular disrupting agents for the treatment of lung cancer: a review. J Thorac Oncol 2010;5:129-39
   PubMed Web of Science ®Google Scholar
• McKeage M, Baguley B. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 2010;116:1859-71
   PubMed Web of Science ®Google Scholar
• Jain R, Booth M. What brings pericytes to tumor vessels? J Clin Invest 2003;112:1134-6
   PubMed Web of Science ®Google Scholar
• Cao Y, Cao R, Hedlund EM. R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J Mol Med 2008;86:785-9
   PubMed Web of Science ®Google Scholar
• Erber R, Thurnher A, Katsen A, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18:338-40
   PubMed Web of Science ®Google Scholar
• Shih A, Holland E. Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett 2006;232:139-47
   PubMed Web of Science ®Google Scholar
• Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235-53
   PubMed Web of Science ®Google Scholar
• Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-78
   PubMed Web of Science ®Google Scholar
• Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Contr 2002;9:36-44
   PubMedGoogle Scholar
• Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan K, Gerber H, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400
   PubMed Web of Science ®Google Scholar
• Avastin® (bevacizumab) [package insert]. Genentech, Inc, South San Francisco, CA; 2009
   Google Scholar
• Herbst R. Toxicities of antiangiogenic therapy in non-small-cell lung cancer. Clin Lung Cancer 2006;8:S23-30
   PubMed Web of Science ®Google Scholar
• Spigel D, Hainsworth J, Yardley D, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010;28:43-8
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Novello S, Von P, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1835-42
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
   PubMed Web of Science ®Google Scholar
• NEXAVAR (sorafenib) tablets, oral [package insert]. Bayer Healthcare Pharmaceuticals Inc, Wayne, NJ; 2009
   Google Scholar
• Escudier B, Eisen T, Stadler W, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-18
   PubMed Web of Science ®Google Scholar
• Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Novello S, von Pawel J, Reck M. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non–small-cell lung cancer. JCO 2010;28(11):835-42
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, Biesma B, Heigener D, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012;30:25):3084-92
   PubMed Web of Science ®Google Scholar
• Heng D, Kollmannsberger C. Sunitinib. Recent Results Cancer Res 2010;184:71-82
   PubMedGoogle Scholar
• SUTENT® (sunitinib malate) capsules, oral [package insert]. Pfizer Inc, New York, NY; 2010
   Google Scholar
• Socinski M, Novello S, Brahmer J, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-6
   PubMed Web of Science ®Google Scholar
• Novello S, Scagliotti G, Rosell R, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009;101:1543-8
   PubMed Web of Science ®Google Scholar
• United States Federal Drug Administration (FDA): FDA approves new treatment for rare form of thyroid cancer. Vandetanib is first drug approved for medullary thyroid cancer. 2013. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm250168.htm
   Google Scholar
• Mitsudomi T. Advances in target therapy for lung cancer. Jpn J Clin Oncol 2010;40:101-6
   PubMed Web of Science ®Google Scholar
• AstraZeneca Oncology 2009. Vandetanib (Zactima™). Available from: http://www.astrazeneca.com/Media/Press-releases/Article/20091028--AstraZeneca-withdraws-regulatory-submissions-for-Zact [Accessed 29 April 2013]
   Google Scholar
• Wells S, Robinson B, Gagel R, et al. [Abstract OC-021]. Presented at the 14th International Thyroid Conference; 11 – 16 September 2010; Paris, France
   Google Scholar
• Natale R, Thongprasert S, Greco F, et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST) [abstract 8009]. J Clin Oncol 2009;27:409s
   Web of Science ®Google Scholar
• De Boer R, Arrieta O, Gottfried M, et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL) [abstract 8010]. J Clin Oncol 2009;27:409s
   Google Scholar
• Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010;11:619-26
   PubMed Web of Science ®Google Scholar
• Lee J, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non–small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized . double-blind phase III trial (ZEPHYR). J Clin Oncol 2010;28:7525
   Google Scholar
• Hilberg F, Roth G, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-82
   PubMed Web of Science ®Google Scholar
• Roth G, Heckel A, Colbatzky F, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem 2009;52:4466-80
   PubMed Web of Science ®Google Scholar
• Hilberg F, Brandstetter I. Efficacy of BIBF 1120, a potent triple angiokinase inhibitor, in models of human non-small cell lung cancer is augmented by chemotherapy: C7-03. J Thoracic Oncol 2007;2(8):S380
   Web of Science ®Google Scholar
• Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010;16:311-19
   PubMed Web of Science ®Google Scholar
• Okamoto I, Kaneda H, Satoh T, et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 2010;9(10):2825-33
   PubMed Web of Science ®Google Scholar
• Ellis PM, Kaiser R, Zhao Y, et al. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 2010;16(10):2881-9
   PubMed Web of Science ®Google Scholar
• Doebele RC, Conkling P, Traynor AM, et al. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.. Ann Oncol 2012;23(8):2094-102
   PubMed Web of Science ®Google Scholar